N/A N=16 The Effects of Immunotherapy in the Nose
Rhinitis, Allergic, Seasonal
Primary: The Total Number of Differentially Expressed Transcripts. — 119; 49 transcripts
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=58 Allergy Immunotherapy for the Reduction of Asthma
Wheezing · Asthma · Allergy
Primary: Asthma Severity as Measured by the Asthma Severity Score (Averaged up to 36 Months) — 21.95; 25.68; 27.72; 27.85 score on a scale — p=0.38
N/A N=173 Probiotics and Health-related Quality of Life in Individuals With Seasonal Allergies
Healthy
Primary: Change in Health-related Quality of Life Score From Baseline to the Peak Week of Allergy Season for Probiotic Versus Placebo, as Measured by MiniRQLQ — -0.1946; -0.6772…
Phase 2 N=75 Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
Peanut Hypersensitivity · Food Hypersensitivity · Hypersensitivity
Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005
N/A N=250 Preoperative Survey to Evaluate Patient Allergy
Allergy Drug · Allergic Reaction · Pediatric
Primary: True Allergy (Consistent With an IgE-mediated Reaction) — 135 Allergies
Phase 2 N=47 Effects of Broccoli Sprout Extract on Allergy Rhinitis
Rhinitis,Allergic
Primary: Total Nasal Symptom Score (TNSS) Change From Baseline to 3 Weeks of Randomly Assigned Treatment — -.5277; -.5484; -.8359; -.181 score on a scale
Phase 1 N=28 Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma
Allergy · Asthma
Primary: Proportion of Participants Who Discontinue Study — 7.1 Percentage of Participants
Phase 2 N=51 Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study
Asthma · Allergic Sensitization
Primary: Number of Participants With Allergic Sensitization at Month 36 Status Post Treatment Completion — 22; 19 participants — p=0.28
N/A N=38 Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose
Allergic Airway Disease
Primary: Total Nasal Cell Count in Response to DEP Challenge at 0, 6 and 24 hr With or Without BSE Intervention — 4.44; 4.50; 4.73; 4.70 log cells/mL — p=<0.001
Phase 4 N=119 TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients
Vaccine Responsiveness in Allergy · Vaccine Responsiveness During Allergy De-sensitization Treatment
Primary: Humoral TBE Immunity — 317.90; 250.10; 282.20 titer
N/A N=31 Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy
Asthma
Primary: Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment — 75.0; 69.5; 141.4; 74.8 cumulative breath units
Phase 2 N=60 Multi Immunotherapy to Test Tolerance and Xolair
Food Allergy
Primary: The Number of Participants Able to Tolerate an Oral Food Challenge to 2,000 mg at Least of 2 Allergens at Week 36 (i.e. the End of the Randomized Withdrawal/Tolerance…
Phase 4 N=102 Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen
Seasonal Allergy
Primary: Area Under the Curve [AUC](Total Score of Symptoms Taking Into Account the Total 5 Symptom Score (T5SS) and Consumption of Rescue Medications (RM) on the Y-axis, and…
Phase 2 N=10 Preventing Anaphylaxis With Acalabrutinib
Food Allergy · Food Allergy Peanut
Primary: Highest Dose of Peanut That is Tolerated During Oral Food Challenge — 29; 4,044 mg — p=0.002
Phase 2 N=54 Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)
Rhinitis, Allergic, Perennial · Asthma
Primary: Difference in German Cockroach-Specific Serum IgE Over Time — 2.16; 1.12 Ratio — p=<0.0001
N/A N=18 The Effect of Omalizumab on Responses to Cat Allergen Challenge
Allergic Rhinitis
Primary: Change in Basophil Surface IgE — -95; -10 percentage of basophil surface IgE
N/A N=434 Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy
Allergic Rhinitis
Primary: Current Medication Use Three Years After Diagnosis of AR — 61; 29 percentage of participants
Phase 2 N=12 Subcutaneous Immunotherapy for Mouse in Adults
Asthma · Perennial Allergic Rhinitis
Primary: Number of Reported Adverse Events (AEs) — 9; 1; 1; 2 Events
N/A N=24 Oral Immunotherapy for Peanut and Mammalian Meat Allergies
Food Hypersensitivity
Primary: The Level of Allergen Consumed Post-oral Immunotherapy — 6; 300 milligrams
Phase 1 N=27 Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
Birch Pollen Allergy
Primary: Treatment Emergent Adverse Events — 13; 3; 81; 2 number of adverse events per arm
Phase 2 N=14 Omalizumab in the Treatment of Peanut Allergy
Food Allergy · Peanut Allergy
Primary: Number of Participants Who Experienced a Decrease in Pn-BHR Area Under the Curve (AUC) of > 80% Compared With Baseline Values Before Week 8 — 5; 9 Participants
N/A N=18 Immune Dysfunction in Allergic Asthma
Asthma
Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…
Phase 2 N=240 Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy
Allergic Rhinitis · Rhinoconjunctivitis
Primary: Combined Rhinoconjunctivitis Symptom and Medication Score — 0.86; 0.64; 0.72 score (maximum=3)
N/A N=20 Immune-modulatory Effect of Probiotic Strain on Grass Pollen Allergic Individuals
Seasonal Allergic Rhinitis
Primary: Comparison of Th2 Cytokines (IL-13) Between Placebo and Probiotic Groups at Baseline (Beginning of Product Intake), 4 Weeks (Mid Period of Product Intake) and 8 Weeks…
Phase 4 N=39 Allergic Rhinitis Changes the Sinus Microbiome
Seasonal Allergic Rhinitis
Primary: Total Nasal Symptom Score (TNSS) — 67.1; 78.0 score on a scale — p=0.391
N/A N=23 The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk, and Nut Allergy in Adults
Food Allergy
Primary: Number of the Patients That Achieve Higher Tolerance of Allergen With Immunotherapy — 6; 4; 3 participants
Phase 2 N=46 Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study
Allergic Rhinitis
Primary: Total Nasal Symptom Score After Nasal Allergen Challenge (NAC) — 3.37; 4.71 score on a scale — p=<0.05
Phase 2 N=686 COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…
N/A N=351 Allergens in Inner-City Schools and Childhood Asthma
Asthma
Primary: Maximum Symptom Days/14 Days — 2.7 days
Phase 2 N=19 The Effects of Omalizumab (Anti-IgE) on the Late-phase Response to Nasal Allergen Challenge
Cat Allergy
Primary: The the Size of the 8 Late-phase Skin Response — 54; 0 percentage decline from NAC-1